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Reduced expression of the ICEmrelated protease CPP32
is associated with radiation-induced cisplatin
resistance in HeLa cells
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Summary Low-dose fractionated y-irradiation (three cycles of 5 x 2 Gy) induced cisplatin resistance in HeLa cells. The drug resistance was
modest (Rf of about 2) and stable, similar to that found previously in murine cells after irradiation. In the drug-resistant HeLa-C3 cells, flow
cytometric analysis revealed a decreased number of apoptotic cells compared with the parental cells. Drug resistance was associated with
considerably enhanced expression of the p53 suppressor protein in HeLa-C3 cells aftercisplatin exposure but seemed not to be regulated by
the bcl-2-dependent pathway. Cisplatin resistance correlated with reduced expression of ICE-related proteases (interleukin-1n-converting
enzyme). Basal levels of the 45-kDa precursor ICE protein were reduced in HeLa-C3 cells, while those of the mature 60-kDa heterotetramer
were similar. The CPP32 protease, a member of the ICE family with structural homology but different substrate specificity, was expressed at
a lowered level. After drug exposure, there was a slight increase of CPP32 in HeLa-C3 cells, equivalent to about 45% of the level attained in
the parental cells. This is in contrast to the CPP32 levels measured after irradiation, which were similar in sensitive and in resistant cells. As
the radiosensitivity is unchanged in both cell lines, these results suggest that cisplatin resistance in HeLa-C3 cells is associated with
alterations of a CPP32-linked apoptotic pathway, which is affected by the damage caused by cisplatin but not by irradiation. Whether these
changes are dependent on the observed p53 modifications is now being studied in resistant clones.
Keywords: irradiation; cisplatin resistance; ICE (interleukin-1n-converting enzyme); CPP32; p53; apoptosis
We have recently shown that cisplatin resistance is induced in
murine fibrosarcoma cells by low-dose fractionated y-irradiation.
Resistance was associated with alterations ofthe cGMP-dependent
transduction pathway and could be overcome either by enhanced
cGMP formation (Eichholtz-Wirth, 1995a) or by heat (Eichholtz-
Wirth, 1995b). It was of interest to investigate whether a similar
resistance could also be induced by radiation in human cells. In the
following study, radiation-induced cisplatin resistance is described
after fractionated y-irradiation in HeLa cells. The mechanisms
of resistance, which were different to those described for the
murine cells (Eichholtz-Wirth et al, 1993, 1994), were associated
with altered expression of interleukin-converting enzyme (ICE)-
related proteases.
The ICE-like proteins belong to a class of cysteine proteases
that play a key role in apoptosis. ICE was synthesized as inactive
45-kDa precursor protein, which was processed proteolytically to
yield a large (p20) and a small (plO) subunit (Thomberry et al,
1992; Wilson et al, 1994). These generated the biologically active
60-kDa heterotetramer either by autoprocessing or by coassem-
bling with other family members or with unrelated proteases.
Different ICE transcripts have been identified (Alnemri et al,
1995) that encode catalytically inactive or truncated isoforms that
are able to coassemble and to yield inactive proteases.
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Based on their sequence homology, the members of the ICE
family may be divided in two major subgroups: one with greater
homology to ICE (such as Nedd-2, Ich-1; Wang et al, 1994;
Faucheau et al, 1995), the other to CPP32 (such as Mch-2;
Femandes-Alnemri et al, 1994; Nicholson et al, 1995; Chen et al,
1996). The various ICE-like proteases are characterized by
different substrate specificity and may be specifically inhibited
(Bump et al, 1995; Tewari et al, 1995a). Their activation and mech-
anisms ofregulation are complex and only poorly understood.
Overexpression of ICE-like proteases has been demonstrated to
induce apoptosis (Miura et al, 1993; Fernandes-Alnemri et al,
1994; Faucheau et al, 1995). In the present study, altered expres-
sion ofICE-like proteases is shown to inhibit apoptosis and to be a
mediator ofcellularresistance to cisplatin afterradiation treatment.
MATERIALS AND METHODS
Materials
The following drugs and chemicals were used: cisplatin solution
(Medac, Hamburg); vincristine (Lilly), doxorubicin (Farmitalia),
etoposide (Bristol), Eagle's minimal essential medium (Serva);
bycomycin (Byc Gulden, Konstanz); newborn calf serum (CCPro,
Karlsruhe); all other chemicals were purchased from Sigma
Chemie, Deisenhofen.
For the Western blot analysis, the following antibodies were
used: precICE and ICE, plO(C-20) rabbit PAb (Santa Cruz); p53
DO-7 and bcl-2, mouse MAb (Dako); CPP32, mouse MAb
(Transduction Laboratories).
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Cell culture
HeLa and HeLa-C3 cells were grown as monolayer cultures in
Eagle's minimal medium, containing L-glutamine and supple-
mented with 10% newborn calf serum, 0.01% bycomycin and
0.035% sodium bicarbonate and maintained at 37°C at pH 7.4 in a
controlled atmosphere (3-3.5% carbon dioxide in air).
For the induction of cisplatin resistance, exponentially growing
HeLa cells were subjected to a cycle of fractionated 137CS irradia-
tion (5 x 2 Gy in 7 days). The cells were then subcultured once per
week over 4-6 weeks with parallel checking of drug sensitivity. If
the drug sensitivity was unchanged, the treatment protocol was
repeated. The preirradiated cells were denoted Cl, C2, C3,
according to the number oftreatment cycles.
Determination of drug and radiation sensitivity
To establish cisplatin survival curves, exponentially growing cells
were appropriately diluted and allowed to attach to the glass
surface overnight. The drugs were freshly diluted in Hanks' solu-
tion and added to the culture medium. After a 1-h exposure period,
the medium was withdrawn, the cells rinsed with Hanks' solution
and fresh culture medium was added. To assess cross-resistance,
cell survival to the following drugs was determined after contin-
uous exposure: cadmium chloride (stock solution 10 mm in water),
vincristine liquid (1 mg ml-1 vincristine sulphate), doxorubicin
(2 mg ml' injection solution, Farmitalia), etoposide (20 mg ml'
infusion concentrate, Bristol). To generate radiation survival
curves, cells were exposed to graded single doses ofy-rays from a
Gammacell 40 caesium-137 source at a dose rate of 1.2 Gy min-'.
After7-9 days ofincubation, all flasks were stained and scored for
colonies of 50 or more cells. The surviving fraction (SF) was
corrected for the plating efficiency ofuntreated cells.
Resistance factors (Rf) were calculated from the ICIO values of
the survival curves. The ICIO is the drug concentration at a given
exposure time required to reduce cell survival to 10%. Data from
cell survival experiments are means of at least three independent
experiments. Standard deviation bars are shown except when the
error is less or equal to the symbol size. P-values are given for
statistical significance between various treatment procedures;
values less than 0.05 were considered to be statistically significant.
Flow cytometry
All FACS measurements required a cell number of 0.5 x 106. For
the cell cycle analysis, the nuclei were prepared according to the
method developed by Nuisse and Kramer (1984). The tissue culture
medium was collected, combined with the trypsinized cells and
centrifuged for 7 min at 100g. After removing the supermatant
completely, the cell pellet was slightly shaken. The cells were first
incubated for 30 min with 1 ml of solution I (584 mg 1-' sodium
chloride, 1 g 1- sodium citrate, 10 mg 1- RNAase, 0.3 ml of
Nonidet P40 and 25 mg 1- ethidium bromide) at room temperature
and after another 30 min, 1 ml of solution II was added (15 g 1-'
citric acid, 0.25 M sucrose and 40 mg 1-' ethidium bromide).
Until use, samples could be stored in the dark at 4°C for at least
1-2 weeks.
For the measurement of apoptotic cells, the Annexin-V-Fluos
Kit from Boehringer Mannheim was used. The preparation,
staining and measurement ofthe cells was carried out according to
the manufacturer's instruction.
The cells were analysed in a FACStar+ cell sorter (Becton
Dickinson), equipped with two argon ion lasers (Innova 90,
Coherent). All dyes were excited with the 488-nm line. Ethidium
bromide (EB) and propidium iodide (PI) fluorescence were
detected at wavelengths above 590 nm. Fluorescein (FITC)
fluorescence was detected by a bandpass filter at 530 nm. For
each sample, 20 000 events were acquired. All parameters
were recorded in logarithmic scale and the data were analysed
with the Data Analysis System (DAS) software developed by
Beisker (1994).
Western blot analysis
Approximately 2 x 106 cells were detached from the glass surface,
washed with phosphate-buffered saline (PBS) and centrifuged.
The pellet was resuspended in lysis buffer [Triton-X-l00 1%, Tris
25 mm, sodium chloride 120 mm, phenylmethylsodiumazide
(PMSF) 1 mM, Natriumorthovanidate 1 mM] and incubated on
ice for 5 min. The lysate was clarified by centrifugation (14 000g,
10 min, 4°C). Loading buffer [Tris-HCl pH 6.8 100 mM,
c
0
D 0.1
.C
C')
0.01
0 1 2 3 4 5
Cisplatin concentration (jig ml-1)
Figure 1 Cell survival of HeLa cells after a 1-h cisplatin exposure, showing
the development of drug resistance as a function of conditioning radiation
treatment. -0-, Control; -7-, two conditioning cycles (1Ox 2 Gy); -0-, three
conditioning cycles (15x 2 Gy). Data for each curve represent one typical
experiment (± s.d.)
Table 1 Sensitivity of HeLa and HeLa-C3 cells to various drugs
Cell lines Doxorubicin Etoposide Vincristine Cadmium chloride
HeLa 0.022 ± 0.005 0.23 ± 0.04 0.0135 + 0.0009 71.4 ± 6.5
HeLa-C3 0.026a ± 0.002 0.21 a ± 0.04 0.0015b + 0.0004 76.9a ± 4.8
All figures are the IC0 drug concentrations (,ug ml-') necessary to reduce cell survival to 10% after continuous drug exposure as derived from survival. aNot
significantly different for HeLa and HeLa-C3 cells. bp < 0.01.
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Figure 2 Radiation sensitivity of parental HeLa (-0-) and resistant HeLa-
C3 cells (-0-). Data points are means (± s.d.) of at least three individual
experiments
Dithiothreitol (DTT) 200 mm, sodium dodecyl sulphate (SDS) 4%,
bromophenol blue 0.2%, glycerol 20%] was added to the super-
natant and the samples were stored at - 18°C until use. The protein
lysate was adjusted to the cell number. Total cellular protein was
assayed according to the procedure of Lowry et al (1951), with
bovine serum albumin serving as standard.
Before separation, the probes were heated at 90°C for 5 min,
resolved on SDS-polyacrylamide gels (10-12%) and transferred
on a polyvinyldifluoride (PVDF) membrane in TBS-T buffer
(20 mm Tris, 137 mm sodium chloride, 1 M hydrochloric acid,
0.1% Tween 20). After blocking with 5% skimmed milk, the
membranes were exposed to the primary antibody (1 jg ml-', ON).
The filters were washed with TBS-T followed by incubation with
the second antibody for 2 h at room temperature. The filters were
washed again and then developed. The detection was accom-
plished with the enhanced chemiluminescence (ECL) method. The
western blots were analysed using Pharmacia Biotech software
Image Master ID.
RESULTS
After three cycles offractionated y-radiation treatment, HeLa cells
developed a moderate cisplatin resistance (Rf = 2.1), which had
been stable for more than 150 cell generations (Figure 1). The
drug-resistant HeLa-C3 cells exhibited similar doubling times
as HeLa cells (20.5-23 h) and a similar protein content (175-
195 ,ug 0I cells). HeLa-C3 cells slightly changed theirphenotype
with more polyhedric morphology compared with the more elon-
gated shape ofthe parental cells. As in murine cells aftery-irradia-
tion, there was no cross-resistance to irradiation (Figure 2). Also,
the sensitivity to doxorubicin and etoposide was unchanged,
whereas the sensitivity to vincristine was enhanced (Table 1).
Metallothioneins were unaltered, as evidenced by the identical
toxicity to cadmium (an indirect measure ofmetallothioneins).
By flow cytometric cell cycle analysis, no differences between
Hela and HeLa-C3 cells were found. The analysis of apoptotic
cells with the Annexin-V-Fluos Kit was based on plasma
membrane alterations occurring during the apoptotic process.
Phosphatidylserine (PS) is translocated to the outer leaflet of the
plasma membrane and can thus be detected by the fluorescein-
labelled protein Annexin-V, which has a high affinity for PS.
Figure 3A demonstrates the differences in the number ofapoptotic
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Figure 3 Flow cytometric analysis of the number of apoptotic cells in HeLa
and HeLa-C3 cells. (A) Apoptotic cells 48 h after cisplatin exposure (0.5 and
5.0 igg ml-' for 1 h) or aftery-irradiation (7.5 Gy). Mean value ±s.d. from three
independent experiments with 6-8 single samples. (B) Time course of
apoptotic cells 18, 24, 48 and 72 h after cisplatin exposure (5.0jg ml-' for
1 h). Single experiment with triplicate data points. Apoptosis was assessed
with the Annexin-V-fluos kit. O, Hela; 2, Hela-C3
cells in both populations 48 h after cisplatin exposure (0.5 or
5.0 jig ml- for 1 h) and 48 h after y-irradiation (7.5 Gy). In the
parental HeLa cells, there was a considerable increase in apoptotic
cells from 4.8 ± 1.4% (control) to 27.1 ± 2.2% after the low and to
58.6 ± 7.3% after the high drug dose; in the resistant HeLa-C3
cells, this increase was significantly ,lower (7.5 ± 1.5% and
30.6 ± 10.6% respectively). A time-course study also revealed
differences in the entry into apoptosis between both cell lines
(Figure 3B). In Hela cells, the number ofapoptotic cells increased
continuously after cisplatin exposure and reached a plateau after
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Figure 4 Expression of apoptosis-related proteins in HeLa and HeLa-C3
cells after cisplatin exposure. Western blot analysis was performed before
(controls, El) and 24 h after a 1-h cisplatin exposure (5 9g ml-1, E), using the
following proteins: p53 (A), bcl-2 (B) and the 45-kDa ICE precursor protease
(C). Mean relative chemiluminescence ± s.d. of three or more experiments
48 h. In the resistant population, a significant increase in apoptotic
cells was observed only 48 h after drug exposure. However, in
HeLa-C3 cells, the variation was high and the increase after 18 h
was not significant. After y-irradiation, the number of apoptotic
cells remained below 10% in both cell lines after 24 h (not shown)
and 48 h (Figure 3A).
One of the main regulatory proteins involved in apoptosis and
also associated with cisplatin resistance (Kastan et al, 1992;
Tishler et al, 1993) is the p53 protein. Basal levels of this protein
are low in HeLa and HeLa-C3 cells (Figure 4). Twenty-four hours
after a 1-h cisplatin exposure, about threefold higher p53 protein
levels were found in the resistant compared to the parental cells.
The elevation of the p53 protein was observed between 16 and
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Figure 5 Time course of protein expression in HeLa and HeLa-C3 cells
after cisplatin exposure and 24 h after y-irradiation. Western blots were
prepared for HeLa (E) and HeLa-C3 cells (l1) after a 1-h cisplatin treatment
(5 ,ug ml-') or after 7.5 Gy. The following proteins were analysed: p53,
bcl-2, CPP32 and precursor ICE protease. Data are from one experiment
(time course) or are mean relative values of different experiments ± s.d.
(y-irradiation)
30 h post drug exposure (Figure 5). At 48 h, the protein level had
almost declined in both cell lines. After irradiation (24 h after 7.5
Gy), the suppressor protein was also expressed at a higher rate in
HeLa-C3 cells. Among the p53-dependent apoptotic proteins,
increased bcl-2 formation may be associated with drug resistance.
As the expression of this anti-apoptotic protein is slightly reduced
in HeLa-C3 compared with HeLa cells (Figure 4) and as differ-
ences in stability seem to be small (Figure 5), there is no indication
of an involvement of this protein in the development of cisplatin
resistance in HeLa-C3 cells.
Significant differences between HeLa and HeLa-C3 cells were
demonstrated in the expression of ICE-related proteins. The
formation of the catalytically inactive 45-kDa precursor ICE
protein was reduced in HeLa-C3 cells and amounted to only about
35% of the basal level in HeLa cells (Figure 4). The precursor
ICE-IgG did not cross-react with ICE plO or p20 subunits. After
drug exposure or after irradiation (Figure 5), these differences in
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Figure 6 Protein expression of CPP32 cysteine protease in HeLa and
HeLa-C3 cells. Western blot analysis was performed in untreated controls,
24 h after a 1-h cisplatin exposure (5,ug ml-') or 24 h after exposure to
7.5 Gy. Mean relative chemiluminescence ± s.d. of three or more
experiments
protein expression persisted. Basal levels of the catalytically active
60-kDa heterotetramer were similar in both cell lines (relative
chemiluminescence 9.0 for HeLa and 8.7 for HeLa-C3 cells). The
protease CPP32, a member of the ICE family, displayed consider-
ably lower basal protein levels in the resistant HeLa-C3 cells. After
cisplatin treatment, CPP32 increased in both cell lines, but only
about 45% of the protease level, measured in the parental cells,
was attained in the resistant population (Figure 6). After irradiation
(24 h after 7.5 Gy), the same expression of CPP32 protein was
found in both cell lines.
DISCUSSION
ICE-related proteases play a central role in the induction and
execution of apoptosis. Their additional importance in the regula-
tion of apoptosis was demonstrated in our study. Alteration of the
expression of ICE-related proteases is associated with the develop-
ment of cellular resistance in HeLa-C3 cells. CPP32, a member of
the ICE family, which is expressed at a reduced rate in HeLa-C3
cells, is probably differentially affected or regulated by the type of
insult or damage involved. The signalling pathway and/or the
DNA cross-linking damage caused by cisplatin induces a lower
CPP32 level in HeLa-C3 cells. Radiation damage that finally leads
to single- and double-strand breaks results in similar CPP32
protein expression in HeLa and HeLa-C3 cells, in accordance with
their identical cellular radiosensitivity. The induction and regula-
tion of the apoptotic pathway is complex and only poorly under-
stood. The growing family ofICE-related proteases are involved in
the death-signalling pathways in an intricate pattem ofcooperation
and interaction. These proteases are characterized by structural
homology and different, but overlapping, substrate specificity
(Femandes-Alnemri et al, 1994; Faucheau et al, 1995; Nicholson
et al, 1995; Tewari et al, 1995b). Whether the various isoforms act
in parallel or sequentially and how their signal is amplified - a
process necessary for rapid apoptosis - is still unknown. Moreover,
not all the activation processes that have been demonstrated in
vitro may be relevant in vivo (Enari et al, 1995). In HeLa-C3 cells,
lower basal levels of preICE (but not of the mature ICE) and
reduced levels ofCPP32 after cisplatin exposure (but not after irra-
diation) were demonstrated to be involved in the regulation of
cisplatin resistance. However, there are probably far more
proteases that are altered and that may affect the signalling
pathway of cisplatin repair. CPP32 is synthesized as an inactive
precursor; the mature protease is generated by autocatalysis or by
other proteases, such as ICE (Fernandez-Alnemri et al, 1994;
Tewari et al, 1995b).
CPP32 is supposed to act downstream of ICE, suggesting that
reduced induction of CPP32 in HeLa-C3 cells may be associated
with decreased activation due to the low precursor ICE protein
levels in these cells. The mature protein can also be formed from
truncated or mutant subunits, such as ICEe, which are efficiently
transcribed, translated and folded and which act as dominant
inhibitors of ICE activity (Wilson et al, 1994; Alnemri et al, 1995).
If such mutant proteins are also formed under physiological condi-
tions or in response to stress, they may alter or inactivate the apop-
totic pathway, as in HeLa-C3 cells. Therefore, the unchanged
expression of the mature 60-kDa ICE protein in HeLa-C3 cells
does not provide evidence about the activity of the protein. A
correlation of protein expression and enzyme activity in HeLa and
HeLa-C3 cells will be the subject of further experimental study.
Viral inhibitors of CPP32 have been described, such as the
cytokine response modifier A (CrmA) (Miura et al, 1993; Tewari
and Dixit, 1995) or the baculovirus gene product p35 (Bump et al,
1995). However, it is not known whether there are cellular homo-
logues of these viral inhibitors of ICE-like proteases that might
also be involved in the induction of cellular drug resistance in
HeLa-C3 cells.
One of the possible substrates for CPP32 is PARP, an enzyme
that is involved in DNA repair and genomic surveillance and
integrity (Nicholson et al, 1995; Tewari et al, 1995b). At the onset
of apoptosis, PARP is proteolytically cleaved, which highly
activates an endonuclease implicated in intemucleosomal DNA
cleavage. In HeLa-C3 cells, the substrates are not known. It is
speculated that the DNA-cross-linking damage, induced by
cisplatin, could involve repair proteins, such as the high-mobility
group protein (HMG) (Billings et al, 1992; Chow et al, 1995).
These transcription factors function as activators/repressors of
transcriptional regulation by enhanced binding to target promotor
sequences. Overexpression of damage recognition proteins, also a
possible substrate of ICE-related proteins, has been implicated in
cisplatin resistance in HeLa cells (Chao et al, 1991).
Reduced expression of the ICE-related proteases correlates with
reduced induction of apoptosis. After cisplatin exposure, the
number of apoptotic cells is considerably lower in the drug-resis-
tant than in the parental cells. There is evidence that the p53
suppressor protein affects the induction of apoptosis; however,
only some, not all, apoptotic pathways are p53-dependent. Wild-
type p53 function is essential for cellular response to DNA
damage. The suppressor protein that is post-transcriptionally regu-
lated may differ in protein stability and also in the expression of
various mutant forms that functionally inactivate the protein. In
HeLa-C3 cells, the p53 protein level is significantly elevated
compared with the parental cells. In this study, it is not possible
to differentiate between wild-type and mutant p53 suppressor
protein, as the antibody used reacts with both types. Determination
of the proportion of wild-type protein and of mutant p53 forms
would give additional information on the involvement of this
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regulatory protein in radiation-induced alterations in HeLa-C3
cells. Moreover, there is no evidence to indicate whether the
enhanced p53 protein expression after cisplatin exposure in HeLa-
C3 is associated with alterations of ICE-related proteases. After
cisplatin treatment, HeLa-C3 cells exhibit a much lower fraction
ofapoptotic cells along with an increased level ofp53; after irradi-
ation, p53 is again increased, but the number of apoptotic cells is
low and similar in both cell lines. Whether and how p53 affects the
induction of apoptosis and/or cisplatin resistance in HeLa cells is
an open question. The above studies have been carried out in HeLa
cells conditioned by three cycles offractionated irradiation, which
gives rise to an uncloned heterogeneous population. More detailed
studies on the involvement of altered p53 in the regulation of
cisplatin resistance in HeLa-C3 cells will now be initiated using
single isolated clones to avoid interfering or overlapping effects.
One of the various p53-dependent proteins that is implicated in
apoptosis is the bcl-2 protein. In HeLa-C3 cells, this protein does
not seem to be associated with the regulation of cisplatin resis-
tance. This anti-apoptotic protein remains at similar or slightly
reduced levels in the resistant HeLa-C3 compared with the
parental HeLa cells. Also, regulatory functions described for bcl-2
in the suppression of ICE proteins (Miura et al, 1993) may there-
fore not operate in cisplatin resistance in HeLa-C3 cells. However,
bcl-2 is only one of several anti-apoptotic proteins in this death
pathway, and it would be interesting to know whether other family
members (such as bcl-xL) are involved or whether the ratio ofpro-
and anti-apoptotic proteins is changed. Again, as mentioned above
for the p53 data, modified protein expression of individual clones
may be masked in these experiments.
Ourpresent study was planned to investigate the development of
cisplatin resistance of an uncloned human cell population after
fractionated y-irradiation and to determine which cell death path-
ways are altered. More detailed studies on the mechanisms of
resistance will now be carried out with individual resistant clones.
In summary, we conclude that low-dose y-irradiation induces
moderate, but stable, cisplatin resistance in HeLa cells. Drug resis-
tance is associated with increased levels of p53 protein and
decreased levels of ICE-related proteases. As the response to radi-
ation is unaltered both in terms ofcell survival and CPP32 expres-
sion, the results suggest that CPP32 is involved in the signalling
cascade of the death pathway initiated by cisplatin but not radia-
tion damage.
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